MX2007004596A - Nitrobenzoindoles y su uso en terapia del cancer. - Google Patents

Nitrobenzoindoles y su uso en terapia del cancer.

Info

Publication number
MX2007004596A
MX2007004596A MX2007004596A MX2007004596A MX2007004596A MX 2007004596 A MX2007004596 A MX 2007004596A MX 2007004596 A MX2007004596 A MX 2007004596A MX 2007004596 A MX2007004596 A MX 2007004596A MX 2007004596 A MX2007004596 A MX 2007004596A
Authority
MX
Mexico
Prior art keywords
cancer therapy
nitrobenzindoles
drugs
radiosensitizers
indoles
Prior art date
Application number
MX2007004596A
Other languages
English (en)
Inventor
William Alexander Denny
William Robert Wilson
Shangjin Yang
Ralph James Stevenson
Moana Tercel
Graham John Atwell
Adam Vorn Patterson
Frederik Bastiaan Pruijn
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of MX2007004596A publication Critical patent/MX2007004596A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere generalmente a nitro-1,2-dihidro-3H-benzo[e]indoles y analogos relacionados, a su preparacion, y a su uso como farmacos selectivos de hipoxia y radiosensibilizadores para terapia de cancer, ambos juntos o en combinacion con radiacion y/u otros farmacos anticancerigenos.
MX2007004596A 2004-10-22 2005-10-21 Nitrobenzoindoles y su uso en terapia del cancer. MX2007004596A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ536107A NZ536107A (en) 2004-10-22 2004-10-22 Nitrobenzindoles and their use in cancer therapy
PCT/NZ2005/000278 WO2006043839A1 (en) 2004-10-22 2005-10-21 Nitrobenzindoles and their use in cancer therapy

Publications (1)

Publication Number Publication Date
MX2007004596A true MX2007004596A (es) 2007-06-22

Family

ID=36203204

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004596A MX2007004596A (es) 2004-10-22 2005-10-21 Nitrobenzoindoles y su uso en terapia del cancer.

Country Status (14)

Country Link
US (1) US7718688B2 (es)
EP (1) EP1809603A4 (es)
JP (1) JP2008517905A (es)
KR (1) KR20070083806A (es)
CN (1) CN101044114B (es)
AU (1) AU2005296389B2 (es)
BR (1) BRPI0517285A (es)
CA (1) CA2584702A1 (es)
IL (1) IL182652A0 (es)
MX (1) MX2007004596A (es)
NZ (1) NZ536107A (es)
RU (1) RU2007118938A (es)
WO (1) WO2006043839A1 (es)
ZA (1) ZA200703699B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940784B2 (en) 2006-02-02 2015-01-27 Syntarga B.V. Water-soluble CC-1065 analogs and their conjugates
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US8076491B2 (en) 2007-08-21 2011-12-13 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
WO2009025793A2 (en) * 2007-08-21 2009-02-26 Senomyx, Inc. Human t2r bitterness receptors and uses thereof
NZ571028A (en) * 2008-09-03 2011-01-28 Auckland Uniservices Ltd Nitrobenzindole compounds and their use in cancer treatment
HUE035798T2 (en) * 2008-11-03 2018-05-28 Syntarga Bv CC-1065 analogues and conjugates
HUE030846T2 (en) 2010-04-21 2017-06-28 Syntarga Bv Conjugates of CC-1065 analogues and bifunctional linkers
CN102827061A (zh) * 2012-09-19 2012-12-19 兰州大学 5,6,7-三甲氧基吲哚类衍生物、制备方法及用途
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
AU2015205574B2 (en) 2014-01-10 2019-08-15 Byondis B.V. Method for purifying Cys-linked antibody-drug conjugates
CA2935433C (en) 2014-01-10 2019-04-02 Synthon Biopharmaceuticals B.V. Duocarmycin anti-her2 antibody drug conjucates with activity against her2 expressing malignancies
CA2935430C (en) 2014-01-10 2018-09-18 Synthon Biopharmaceuticals B.V. Duocarmycin adcs for use in treatment of endometrial cancer
WO2016001485A1 (en) 2014-06-30 2016-01-07 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
WO2019004413A1 (ja) * 2017-06-30 2019-01-03 東レ株式会社 インドリン誘導体及びそれを含む細胞毒性剤
CN112724068A (zh) * 2020-12-30 2021-04-30 蔡桂坡 具有hdac抑制活性的吲哚类衍生物的合成方法及肿瘤应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69734722T2 (de) * 1996-09-12 2006-07-20 Auckland Uniservices Ltd. Kondensierte n-acylindole als antitumormittel
DE60211905T2 (de) * 2001-02-22 2007-01-18 School Of Pharmacy, University Of London Benz-indol- und benzo-chinolin-derivate als prodrugs zur tumorbehandlung
WO2003097635A1 (en) 2002-05-17 2003-11-27 Auckland Uniservices Limited Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl(amine-derived)] compounds and analogues thereof, and to products obtained therefrom
NZ529249A (en) 2003-10-31 2006-04-28 Auckland Uniservices Ltd Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic

Also Published As

Publication number Publication date
ZA200703699B (en) 2008-10-29
CN101044114A (zh) 2007-09-26
AU2005296389A1 (en) 2006-04-27
BRPI0517285A (pt) 2008-10-07
AU2005296389B2 (en) 2012-03-15
EP1809603A4 (en) 2009-09-02
JP2008517905A (ja) 2008-05-29
KR20070083806A (ko) 2007-08-24
RU2007118938A (ru) 2008-11-27
CN101044114B (zh) 2012-02-15
US7718688B2 (en) 2010-05-18
CA2584702A1 (en) 2006-04-27
WO2006043839A1 (en) 2006-04-27
EP1809603A1 (en) 2007-07-25
NZ536107A (en) 2007-06-29
US20080119442A1 (en) 2008-05-22
IL182652A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
MX2007004596A (es) Nitrobenzoindoles y su uso en terapia del cancer.
TW200600091A (en) Sulfonylethyl phosphorodiamidates
IL186230A0 (en) Anticancer combination therapy using sunitinib malate
WO2001012199A3 (en) Methoxyamine potentiation of temozolomide anti-cancer activity
WO2010110685A3 (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2007033023A3 (en) Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
EP2056818A4 (en) COMPOSITIONS AND METHODS FOR NEUROPROTECTION
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
EP1713474A4 (en) INDIRUBINE DERIVATIVES WITH ANTICANCER PROPERTIES AGAINST CANCER CELLS IN HUMANS
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
WO2008089397A3 (en) Adrb2 cancer markers
MY146112A (en) Long-term feed - cancer patient
WO2007117161A1 (en) Substituted ring fused azines and their use in cancer therapy
WO2011054837A3 (de) Bifunktionale prodrugs und drugs
WO2007019308A3 (en) Illudin analogs useful as anticancer agents
WO2005076888A3 (en) Anti-cancer therapies
IL178939A (en) Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer
HK1105886A1 (en) Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours l-733060
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
ZA200701578B (en) Combination anticancer therapy and pharmaceutical compositions therefore
WO2011056566A3 (en) Compounds and methods for treatment of cancer
ZA200708873B (en) Anticancer combination therapy using sunitinib malate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal